Mattia Boeri
Overview
Explore the profile of Mattia Boeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Borzi C, Ganzinelli M, Caiola E, Colombo M, Centonze G, Boeri M, et al.
J Thorac Oncol
. 2021 Apr;
16(8):1298-1311.
PMID: 33887464
Introduction: Preclinical models recently unveiled the vulnerability of LKB1/KRAS comutated NSCLC to metabolic stress-based treatments. Because miR-17 is a potential epigenetic regulator of LKB1, we hypothesized that wild-type LKB1 (LKB1)...
12.
Sozzi G, Manenti A, Boeri M, Sabia F, Montomoli E, Pastorino U, et al.
Tumori
. 2021 Apr;
107(5):472-473.
PMID: 33877026
No abstract available.
13.
Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, et al.
Tumori
. 2020 Nov;
107(5):446-451.
PMID: 33176598
There are no robust data on the real onset of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and spread in the prepandemic period worldwide. We investigated the presence of...
14.
Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, et al.
Transl Lung Cancer Res
. 2020 Jul;
9(3):617-628.
PMID: 32676324
Background: Several biomarkers have been separately described to select patients for immunotherapy (IO), but few studies integrate these markers. Di Maio, EPSILoN and the plasma microRNA signature classifier (MSC), are...
15.
Milione M, Boeri M, Cantarutti A, Centonze G, Busico A, Suatoni P, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32646072
Almost 25% of lung cancers (LCs) occur in never-smokers. LC inflammatory profile, based on plasma C-reactive protein levels (CRP), predicts mortality, independently by smoking-status. We hypothesized that: CRP could be...
16.
Sestini S, Boeri M, Marchiano A, Pelosi G, Galeone C, Verri C, et al.
Oncotarget
. 2019 Nov;
10(57):6043.
PMID: 31666934
[This corrects the article DOI: 10.18632/oncotarget.5210.].
17.
Gasparini P, Fortunato O, De Cecco L, Casanova M, Ianno M, Carenzo A, et al.
Cancers (Basel)
. 2019 Sep;
11(9).
PMID: 31533233
Adolescents and young adults (AYA) with rhabdomyosarcoma (RMS) form a subgroup of patients whose optimal clinical management and access to care remain a challenge and whose survival lacks behind that...
18.
Fortunato O, Gasparini P, Boeri M, Sozzi G
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31242686
Lung cancer is the predominant cause of cancer-related deaths. The high mortality rates are mainly due to the lack of diagnosis before the cancer is at a late stage. Liquid...
19.
Platania M, Pasini F, Porcu L, Boeri M, Verderame F, Modena Y, et al.
Lung Cancer
. 2019 May;
132:17-23.
PMID: 31097088
Background: Oral vinorelbine administered at the maximum tolerated dose has already showed activity and a good safety profile in advanced non-small-cell lung cancer (NSCLC). The MA.NI.LA study was a phase...
20.
Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Galeone C, et al.
Clin Cancer Res
. 2019 Jan;
25(7):2166-2173.
PMID: 30617131
Purpose: Immune-checkpoint inhibitors (ICI) have improved the survival of patients with non-small cell lung cancer (NSCLC). However, only a subset of patients benefit from ICIs, and the role of PD-L1...